Atrium Therapeutics, Inc. (RNA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 141.29M USD. 52-week range 7.63 to 16.77 USD. Data as of 2026-10-09.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac ...